Durvalumab + tremelimumab immune checkpoint inhibition
Description NMA NMA

CP 675206 - CP675206 - CP-675206 - CP-675,206 - CP-675 - P675 cpd - CP 675 - ticilimumab      

  • Group by...

pdf
pathology k Demonstrated benefit and harm      



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons